Hamdi A Jama1,2, David M Kaye1,3,4, Francine Z Marques1,5. 1. Heart Failure Research Group, Baker Heart and Diabetes Institute. 2. Department of Pharmacology, Faculty of Medicine Nursing and Health Sciences, Monash University. 3. Central Clinical School, Faculty of Medicine Nursing and Health Sciences, Monash University. 4. Heart Centre, Alfred Hospital. 5. School of Biological Sciences, Faculty of Science, Monash University, Melbourne, Victoria, Australia.
Abstract
PURPOSE OF REVIEW: To summarize evidence supporting that microorganisms colonizing our gastrointestinal tract, collectively known as the gut microbiota, are implicated in the development and maintenance of hypertension in experimental models. RECENT FINDINGS: The use of gnotobiotic (germ-free) mice has been essential for advancement in this area: they develop higher blood pressure (BP) if they receive faecal transplants from hypertensive patients compared to normotensive donors, and germ-free mice have a blunted response to angiotensin II. Experimental hypertension is consistently accompanied by changes in the composition of the gut microbiota. This is combined with a shift in microbial diversity and the deterioration of the gut epithelial barrier commonly referred to as gut dysbiosis. Restoration of normal gut biosis and microbiota alleviates and protects against the development of hypertension in both genetic and pharmacological models. This has been achieved by the use of antibiotics, faecal transplants between normotensive and hypertensive strains, and the use of prebiotics (i.e. food stuff that feeds the microbiota), probiotics (i.e. live bacteria) and gut metabolites (i.e. short-chain fatty acids). SUMMARY: Research into experimental hypertension supports that the gut microbiota contributes to the regulation of BP. Manipulation of the microbiota might represent a new tool to prevent hypertension.
PURPOSE OF REVIEW: To summarize evidence supporting that microorganisms colonizing our gastrointestinal tract, collectively known as the gut microbiota, are implicated in the development and maintenance of hypertension in experimental models. RECENT FINDINGS: The use of gnotobiotic (germ-free) mice has been essential for advancement in this area: they develop higher blood pressure (BP) if they receive faecal transplants from hypertensivepatients compared to normotensive donors, and germ-free mice have a blunted response to angiotensin II. Experimental hypertension is consistently accompanied by changes in the composition of the gut microbiota. This is combined with a shift in microbial diversity and the deterioration of the gut epithelial barrier commonly referred to as gut dysbiosis. Restoration of normal gut biosis and microbiota alleviates and protects against the development of hypertension in both genetic and pharmacological models. This has been achieved by the use of antibiotics, faecal transplants between normotensive and hypertensive strains, and the use of prebiotics (i.e. food stuff that feeds the microbiota), probiotics (i.e. live bacteria) and gut metabolites (i.e. short-chain fatty acids). SUMMARY: Research into experimental hypertension supports that the gut microbiota contributes to the regulation of BP. Manipulation of the microbiota might represent a new tool to prevent hypertension.
Authors: Saroj Chakraborty; Juthika Mandal; Tao Yang; Xi Cheng; Ji-Youn Yeo; Cameron G McCarthy; Camilla F Wenceslau; Lauren G Koch; Jennifer W Hill; Matam Vijay-Kumar; Bina Joe Journal: Hypertension Date: 2020-04-27 Impact factor: 10.190
Authors: Carla B P Silva; Jefferson Elias-Oliveira; Cameron G McCarthy; Camilla F Wenceslau; Daniela Carlos; Rita C Tostes Journal: Am J Physiol Heart Circ Physiol Date: 2021-06-18 Impact factor: 5.125
Authors: Aaron L Magno; Lakshini Y Herat; Márcio G Kiuchi; Markus P Schlaich; Natalie C Ward; Vance B Matthews Journal: J Clin Med Date: 2020-08-26 Impact factor: 4.241